Antidiabetics Market 2018: Study on Eminent Players | Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Merck, Boehringer Ingelheim, Novartis, Takeda Pharmaceuticals, Pfizer, Novo Nordisk, Bayer Corporation, Oramed Pharmaceuticals, Halozyme Therapeutics, J

Antidiabetics Market will reach USD 116.1 billion by 2024 as per a new research report.

Growing prevalence of diabetes worldwide coupled with presence of strong product pipeline will drive industry growth over the forecast timeframe. Rising demand of insulin analogs for the treatment of type I and type II diabetes along with rising geriatric population should fuel global antidiabetics market growth.

Increasing obese population will substantially influence the antidiabetics industry , as obesity is major factor responsible for developing coronary heart diseases, high BP, diabetes and stroke leading to death.

Antidiabetics market growth will be hindered by the unaffordable prices of insulin used to treat patient base suffering from diabetes. Soaring cost of insulin vials is expected to impede the market growth over the forecast timeline.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/504

Insulin product dominated the industry owing to the high prevalence of diabetes globally. Also, the demand for long acting and rapid acting insulin analogs increases due to adoption of unhealthy dietary habits leading to obesity which further leads to increase in market growth over the forecast period. The development of other antidiabetic drugs such as DPP-4 inhibitors and GLP-1 agonist will further witness a significant growth in the future owing to its application to treat type II diabetes.

U.S. antidiabetics market was dominating the industry owing to the presence of geriatric patient pool, developed healthcare facilities and various educational programs to increase awareness levels.

UK antidiabetics market holds the largest regional revenue share due to growing prevalence of diabetes along with the presence of associations providing funds will fuel business growth.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/504

Rising disposable income, large patient pool unmet medical needs will drive the China antidiabetic market. India is the fastest growing economy owing to the presence of high prevalence of lifestyle induced disorders such as diabetes. Also, companies such as Eli Lilly and Novo Nordisk are capitalizing on innovative researches focusing on development of high-efficacy and easy-to-use insulin products to grab market share in the emerging country.

Some of the notable industry players are Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Merck, Boehringer Ingelheim, Novartis, Takeda Pharmaceuticals, Pfizer, Novo Nordisk, Bayer Corporation, Oramed Pharmaceuticals, Halozyme Therapeutics, Johnson & Johnson and AstraZeneca.

Major industry players are increasing their focus on research activities with the presence of considerable number of products in their pipeline. They are also emphasizing on collaborations and partnerships to enhance their existing product portfolio for treatment of diabetes.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

This release was published on openPR.